Outcome of Board Meeting held on 14th November, 2025 to Considered and approved Un-audited Financials Results for the quarter ended on 30th September, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Skybiotech Healthcare Ltd (formerly Kapil Cotex Ltd) approved unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2025 on 14 November 2025. The company recently changed its name (effective 7 November 2025) reflecting a pivot from textiles to healthcare/biotech. Standalone numbers are tiny — H1 FY26 revenue from operations was just Rs 4.50 lakhs versus Rs 5.21 lakhs last year, with a small loss of Rs 0.32 lakhs. The real activity is in the subsidiary Skybiotech Life Sciences Pvt Ltd, which alone reported Rs 194.09 lakhs revenue and a Rs 32.14 lakhs loss for Q2. On a consolidated basis, H1 FY26 revenue grew ~22.6% YoY to Rs 430.47 lakhs (from Rs 351.21 lakhs), but the company swung to a sharp loss of Rs 242.59 lakhs versus Rs 1.87 lakhs loss a year ago. Standalone operating cash flow turned negative at Rs (1.86) lakhs versus Rs 48.30 lakhs positive in the prior period. Auditor SPD & Associates issued an unqualified limited review conclusion.
Despite decent top-line growth driven by the new biotech subsidiary, profitability has collapsed sharply with consolidated losses widening more than 100x, signalling heavy burn at the subsidiary level. Negative operating cash flow and a near-zero cash balance (Rs 1.02 lakhs standalone) raise concerns about the company's ability to fund ongoing operations without further capital infusion.